US FDA panel votes against use of Medtronic’s blood pressure treatment device

This post was originally published on this site

(Reuters) – The U.S. Food and Drug Administration’s independent experts on Wednesday narrowly voted against recommending the approval of Medtronic (NYSE:MDT)’s blood pressure treatment device, saying risks tied to using it do not outweigh the benefits.

The same panel on Tuesday voted in favor of rival ReCor’s device for use in a surgery called renal denervation in patients whose high blood pressure cannot be controlled by drugs.